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ABSTRACT
Objective: To investigate cut-off values for HOMA1-IR and HOMA2-IR to identify insulin resis-
tance (IR) and metabolic syndrome (MS), and to assess the association of the indexes with 
components of the MS. Methods: Nondiabetic subjects from the Brazilian Metabolic Syndrome 
Study were studied (n = 1,203, 18 to 78 years). The cut-off values for IR were determined from 
the 90th percentile in the healthy group (n = 297) and, for MS, a ROC curve was generated for 
the total sample. Results: In the healthy group, HOMA-IR indexes were associated with central 
obesity, triglycerides and total cholesterol (p < 0.001). The cut-off values for IR were: HOMA1-IR 
> 2.7 and HOMA2-IR > 1.8; and, for MS were: HOMA1-IR > 2.3 (sensitivity: 76.8%; specificity: 
66.7%) and HOMA2-IR > 1.4 (sensitivity: 79.2%; specificity: 61.2%). Conclusions: The cut-off 
values identified for HOMA1-IR and HOMA2-IR indexes have a clinical and epidemiological ap-
plication for identifying IR and MS in Westernized admixtured multi-ethnic populations. Arq Bras 
Endocrinol Metab. 2009;53(2):281-287.
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RESUMO
Objetivo: Determinar pontos de corte para os índices HOMA1-IR e HOMA2-IR na identificação 
de resistência à insulina (RI) e síndrome metabólica (SM), além de investigar a associação de 
ambos os índices com os componentes da SM. Métodos: Foram avaliados indivíduos não 
diabéticos (n = 1.203, 18 a 78 anos) participantes do Estudo Brasileiro de Síndrome Metabólica. 
Os pontos de corte para RI foram determinados com base no percentil 90 do grupo saudável 
(n = 297) e, para SM, foi construída uma curva receiver operating characteristic (ROC) para 
toda a amostra. Resultados: No grupo saudável, os índices HOMA-IR associaram-se à obe-
sidade central, aos triglicérides e ao colesterol total (p < 0,001). Os pontos de corte para RI 
foram: HOMA1-IR > 2,7 e HOMA2-IR > 1,8; e, para SM, foram: HOMA1-IR > 2,3 (sensibilidade: 
76,8%; especificidade: 66,7%) e HOMA2-IR > 1,4 (sensibilidade: 79,2%; especificidade: 61,2%). 
Conclusões: Os pontos de corte identificados para os índices HOMA1-IR e HOMA2-IR possuem 
aplicação clínica e epidemiológica na identificação de RI e SM em populações miscigenadas 
multiétnicas ocidentalizadas. Arq Bras Endocrinol Metab. 2009;53(2):281-287.
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InTRODUCTIOn
The metabolic syndrome (MS) is a cluster of obesity, low HDL cholesterol, hypertension, impaired fast-
ing glucose and elevated triglycerides, among other dys-
metabolic conditios, reflecting underlying insulin resis-
tance. MS and insulin resistance are risk factors for type 
2 diabetes and are associated with cardiovascular disease 
morbidity and mortality (1). Insulin resistance and relat-
ed metabolic conditions are becoming increasingly fre-
quent, and a substantial proportion of apparently healthy 
people are reported to be insulin resistant (2,3). 
The homeostatic model assessment (HOMA) is a 
validated method to measure insulin resistance from 
fasting glucose and insulin. The original model HO-
MA1-IR, first published by Mattews and cols. in 1985 
(4), has been widely used, especially in epidemiological 
and clinical studies. Recently, the model was updated 
with some physiological adjustments to a computer 
version (HOMA2-IR) providing a more accurate index 
(5). Previously, our group identified the cut-off value 
of 2.71 for insulin resistance based on the HOMA1-IR 
index distribution in the Brazilian admixtured popula-
tion (6). However, there is a lack of reference values for 
the new model. The spectrum of HOMA-IR indexes in 
populations is ethnic dependence, and specific cut-off 
values should be established to allow its use in differen-
tiating normal from impaired insulin sensitivity (7).
Expert groups have developing a unifying definition 
for the MS. The International Diabetes Federation (IDF) 
established a simple diagnostic tool that is convenient to 
use in clinical practice and can be used and compared 
worldwide (8). The prevalence of MS in Brazilian popula-
tion has been investigated (9-11). Nonetheless, no study 
has evaluated the optimal cut-off values for HOMA-IR 
indexes in identify MS in Brazilian adults.
In light of these observations, the present study aimed: 
to investigate the optimal cut-off values for HOMA1-IR 
and HOMA2-IR to identify insulin resistance and MS in 
Brazilian adults; to compare the ability of both indices to 
identify MS; and to evaluate clinical and metabolic char-
acteristics according to HOMA-IR indexes distribution 
in healthy subjects and in the total studied population, 
including a wide body mass index (BMI) range.
METhODS
Subjects
This study was performed as part of the Brazilian 
Metabolic Syndrome Study (BRAMS), a population 
survey on metabolic disorders. The data of 2,322 sub-
jects were examined from the central database, and 
1,203 of them attended the eligible criteria for the de-
sired analyses: adult (age ≥ 18 years), non-diabetics, and 
fasting glucose (54.1 to 450.5 mg/dL) and specific in-
sulin ranges (2.9 to 43.8 mU/L) in order to allow the 
HOMA2-IR calculations. Afterward, the healthy group 
(n = 297) was defined as: BMI < 30 kg/m², HDL cho-
lesterol ≥ 40 mg/dL, triglycerides ≤ 200 mg/dL, LDL 
cholesterol < 160 mg/dL, fasting plasma glucose < 
100 mg/dL and normotensive status. This study was 
approved by the Ethics Committee of the School of 
Medical Sciences of Universidade Estadual de Campinas 
(Unicamp), and informed consent was obtained from 
each participant. 
Clinical and biochemical analysis 
The anthropometrical measures were assessed by trained 
observers. Weight and height were measured with the 
subjects wearing light clothing and without shoes on. 
The waist circumference was assessed at the mid point 
between the lowest rib and the iliac crist at the end of 
a normal expiration (12). The BMI was calculated and 
classificated according the World Health Organization 
(WHO) recommendation (12). 
Blood pressure measurement was taken according 
to the recommendations of the 5th Brazilian Guide-
lines on Hypertension (13). The auscultatory meth-
od was employed using a suitably calibrated mercury 
sphygmomanometer. The volunteers were in the sitting 
position and at rest for ten minutes. 
Blood samples were obtained after a 12-hour over-
night fast and stored in a freezer at -30ºC. Plasma insu-
lin was determined using a specific radioimmunoassay kit 
(Linco Research Inc.). Glucose was determined by the 
oxidase method. Total cholesterol, HDL cholesterol and 
tryglicerides were measured using the colorimetric enzy-
matic method. LDL cholesterol fraction was calculated 
by the Friedwald’s formula (14). The HOMA1-IR in-
dex was calculated by the formula: HOMA1-IR = fasting 
plasma insulin (µU/ml) x fasting plasma glucose (mmol/
L)/22.5 (4). The HOMA2-IR index was obtained by the 
program HOMA Calculator v2.2.2 (15).
Definition of metabolic syndrome 
The MS was defined using the IDF criteria (8), which 
considers central obesity based on the waist circum-
ference value, plus any two of the following four fac-
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tors: raised triglycerides level (≥ 150 mg/dL) or cur-
rent treatment for this; reduced HDL cholesterol (< 
40 mg/dL in males and < 50 mg/dL in females), or 
current treatment for this lipid; raised blood pressure 
(systolic blood pressure ≥ 130 or diastolic blood pres-
sure ≥ 85 mmHg), or current treatment with an anti-
hypertensive drug (of previously diagnosed hyperten-
sion); raised fasting plasma glucose (≥ 100 mg/dL) or 
previously diagnosed type 2 diabetes.
Statistical analysis
Statistical analysis was performed with the SPSS pro-
gram for Windows (version 12.0). A p value < 0.05 
was considered statistically significant. The Kolmogo-
rov-Smirnov test was applied to assess the assumption 
of normality for the data. Data were reported as mean 
± standard deviation (SD) or median/interquartile 
range, according with the normal distribution status. 
The lower and upper HOMA-IR indexes quartiles were 
compared using the Mann-Whitney test, once the HO-
MA-IR indexes were not normally distributed. The cat-
egories of BMI were compared by the Kruskal-Wallis 
test. The Dunn’s post hoc test was applied for multiple 
comparisons. The cut-off values for insulin resistance 
were based on the 90th percentile in the healthy group. 
For MS, a receiver operating characteristic (ROC) curve 
was generated for the total studied population. The ar-
eas under the ROC curve (AUC) were calculated (16) 
to evaluate the accuracy of the HOMA-IR indexes. The 
greater the AUC, the greater the discriminatory power 
of them for MS. The optimal cut-off value was denoted 
by the value that had the largest sum of sensitivity and 
specificity (17), and, at the same time, sensitivity and 
specificity ≥ 60%. The Z statistic pairwise comparison 
was used to compare the AUC.
RESUlTS
A total of 1,203 subjects aged 18 to 78 years participat-
ed in this study. The main characteristics of the study 
population are presented in Table 1. It is observed a 
balanced distribution of gender; a comprehensive range 
of BMI, concerning eutrophic and obese subjects; and 
a different distribuition for the HOMA-IR indexes, 
that is, the HOMA2-IR presented lower values com-
pared with the first published index. Table 2 shows the 
healthy group caracterization. All of them did not have 
any clinical and metabolic characteristics of MS. They 
were normotensive, normolipidemic, non obese and 
normal glucose tolerants. 
In Figure 1, it is possible to compare the distribu-
tion of anthropometric and metabolic variables accord-
ing the HOMA-IR indexes quartiles in the healthy 
group. The values for waist circumference, BMI, to-
tal cholesterol and triglycerides increased in the upper 
quartiles for both HOMA-IR indexes (p < 0.05). LDL 




Male, n (%) 511 (42.5)
Female, n (%) 692 (57.5)
Age, years 41 (32 to 50)
BMI, kg/m² 29.6 (24.9 to 36.4)
Systolic blood pressure, mmHg 120 (110 to 130)
Diastolic blood pressure, mmHg 80 (70 to 90)
Triglyceride, mg/dL 108.5 (78.0 to 155.5)
Total cholesterol, mg/dL 192.0 (166.0 to 224.0)
HDL cholesterol, mg/dL 46.0 (39.0 to 55.0)
LDL cholesterol, mg/dL 118.0 (95.7 to 145.0)
Fasting plasma glucose, mg/dL 88.0 (81.0 to 96.0)
Fasting plasma insulin, mU/L 10.1 (6.1 to 18.0)
HOMA1-IR 2.2 (1.2 to 4.1)
HOMA2- IR 1.5 (0.9 to 2.6)
BMI = body mass index.
Table 2. Clinical and metabolic characteristics of the healthy group 
Characteristic
Mean ± SD or median 
(interquartile range)  
(n = 297)
Male, n (%) 130 (43.8)
Female, n (%) 167 (56.2)
Age, years 36.0 (27.0 to 46.0)
BMI, kg/m² 23.9 ± 2.9
Systolic blood pressure, mmHg 120 (110 to 120)
Diastolic blood pressure, mmHg 80 (70 to 80)
Triglyceride, mg/dL 78.0 (59.5 to 104.5)
Total cholesterol, mg/dL 177.1 ± 30.9
HDL cholesterol, mg/dL 52.0 (47.0 - 62.0)
LDL cholesterol, mg/dL 104.2 ± 26.7
Fasting plasma glucose, mg/dL 82.7 ± 7.5 
Fasting plasma insulin, mU/L 5.9 (4.6 to 8.9)
HOMA1-IR 1.23 (0.92 to 1.93)
HOMA2- IR 0.87 (0.66 to 1.30)
BMI = body mass index; mean and SD (standard deviation) used for variables with normal 
distribution.
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cholesterol values were higher in the fourth quartile 
only for HOMA1-IR distribuition, and HDL choles-
terol presented no statistically significant difference be-
tween quartiles. 
The comparison of HOMA-IR indexes distribution 
accross the BMI categories in the total studied popula-
tion is presented in Figure 2. The multiple comparisons 
showed a parallel increasing in HOMA-IR indexes with 
a rising in BMI categories (p < 0.001), with an excep-
tion for the highest degress of obesity (obesity grade I/
II versus grade III). The distribuition of HOMA-IR in-
dexes according to MS diagnostic is presented in Figure 
3. Subjects with a positive diagnostic for MS presented 
higher HOMA-IR indexes values (p < 0.001). 
ROC analyse is presented in Figure 4. The AUC for 
the two HOMA-IR indexes were statisticaly significant 
(p < 0.001). HOMA1-IR index presented the largest 
AUC, if compared with HOMA2-IR. Both values were 
slightly different (p < 0.001), with overlapping 95% 
confidence intervals. Table 3 shows the optimal cut-off 
values identified for insulin resistance, considering the 
healthy subjects whose HOMA1-IR values were above 
the 90th percentile, and for MS, taking into account 
the optimal cut-off values in the ROC curve.
Q1 = first quartile; Q4 = fourth quartile; BMI = body mass index; WC = waist circumference; TG = triglyceride; TC = total cholesterol; HDL-C = HDL-cholesterol; LDL-C = LDL-cholesterol; t-test for BMI, WC, 
TC and LDL-C (presented as mean) and Mann-Whitney test for TG and HDL-C (presented as median); * p < 0.05; ** p < 0.001.
Figure 1. Comparison of clinical and metabolic characteristics according to HOMA-IR indexes quartiles in the healthy group.
BMI = body mass index. 
Kruskal-Wallis test. p < 0.001. 





































































≤ 24.9 25.0-29.9 30.0-34.9 35.0-39.9 ≥ 40.0
BMI (kg/m2)





























285Arq Bras Endocrinol Metab. 2009;53/2
MS- = subjects without metabolic syndrome; MS+ = subjects with metabolic syndrome; Mann-Whitney test; p < 0.001.
Figure 3. Box plot comparison of HOMA-IR indexes distribution according to metabolic syndrome diagnostic in the total studied population.
AUC = area under the curve; CI = confidence interval; ** p < 0.001 for null hypothesis: true area 
= 0.5; Z statistic for pairwise comparison of AUC: HOMA1-IR > HOMA2-IR; p < 0.001
Figure 4. Receiver operating characteristic (ROC) curves comparing HOMA-IR 





































Table 3. Cut-off values of HOMA1-IR and HOMA2-IR indexes to identify insulin resistance and metabolic syndrome
Index
Insulin resistance Metabolic syndrome
Cut-off value* Cut-off value ** Sensibility  (95%CI) Specificity (95%CI)
HOMA1-IR 2.7 2.3 76.8 (72.1 - 80.5) 66.7 (63.3 - 70.0)
HOMA2-IR 1.8 1.4 79.2 (74.7 - 82.8) 61.2 (57.6 - 64.6)
CI  = confidence interval; * the 90th percentile in the healthy group; ** the optimal cut-off value verified in ROC analysis.
DISCUSSIOn
The present study investigated the optimal cut-off val-
ues for HOMA1-IR and HOMA2-IR to identify insulin 
resistance and MS in an admixtured population. It was 
also demonstrated that insulin resistance, assessed by 
both HOMA-IR indexes, is associated with an elevated 
BMI, with a worse lipoprotein profile and with a posi-
tive diagnostic for MS. Furthermore, it was verified that 
in the apparently healthy subjects, HOMA-IR indexes 
were positively associated with BMI and abdominal 
obesity, and with triglycerides and total cholesterol.
HOMA1-IR, the first described model, is a vali-
dated method to evaluate insulin resistance. However, 
according to Levy and cols. (5), the original equation is 
now superseded by the new model. The HOMA2-IR is 
a more accurate representation of the metabolic process 
because it models the feedback relationship between in-
sulin and glucose in the various organs in the body (7). 
HOMA1-IR: AUC = 0.78** (CI 95% = 0.76 - 0.81)
HOMA2-IR: AUC = 0.77** (CI 95% = 0.75 - 0.79)
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On the other hand, the HOMA2-IR has the inconve-
nience that only a specific range of values are acceptable 
for calculation. In clinical practice, this limitation makes 
difficult the management of insulin results outside the 
limits and the need for a computer to run the program. 
In this study, the HOMA1-IR showed an AUC statisti-
cally higher than the area verified for the new model, 
but without major clinical relevance, because the values 
of the areas were quite similar (0.77 and 0.78) with an 
overlapping confidence intervals.
Most of the published cut-off points for the HO-
MA-IR indexes are based on measures of dispersion. In 
the past, our group identified the cut-off value of 2.71 
for insulin resistance evaluated by the HOMA1-IR in 
an admixture population (6). In this study, with an up-
dated database and a larger sample, the value of 2.7 
found was equivalent, reinforcing the concept that it 
is a useful reference for the Brazilian adult population. 
The cut-off value of 2.7 shows a hight similarity to early 
reports. Evaluating subjects apparently healthy, Buccini 
and Wolfthal (18) identified the cut-off value of 2.64 in 
Argentinians; Bonora and cols. (19) found the value of 
2.77 in Italians and Yeni-Komshian and cols. (20) veri-
fied the value of 2.7 in North Americans. In contrast, 
Ascaso and cols. (21) found the cut-off value of 3.8 in 
Spanish population. 
For MS, the optimal cut-off value of 2.3 identified 
in the present study was smaller than the value for insu-
lin resistance, probably because the MS involves the di-
agnostic of multiple disorders simultaneously, not only 
the insulin resistance itself, but also main underlying 
pathophysiological condition, the central adiposity. In 
Korean non-diabetic adults Lee and cols. (22) identi-
fied a very similar value of 2.34. Recentely, the cut-off 
value of 2.5 was established for assessing MS in a co-
hort of Brazilian children (23). 
Hence, for HOMA2-IR, there are no stabilished 
reference values for both, insulin resistance and MS, in 
the literature. We identified the cut-off value of 1.8 to 
detect insulin resistance, and of 1.4 for MS. The study 
of Buccini and Wolfthal (18) suggested the value of 
1.67 to detect insulin resistance.
Obese individuals tend to be insulin resistant (24), 
what was demonstrated with the increasing HOMA-
IR indexes gradient across the growing categories of 
BMI. On the other hand, some associations between 
HOMA-IR indexes and components of MS were iden-
tified in the nonobese healthy group. In this group, the 
presence of higher values of BMI, triglycerides, total 
cholesterol and LDL cholesterol in the upper HOMA-
IR indexes quartiles could be explained by the body 
fat distribution, since the waist circumference was also 
increased in the upper HOMA-IR indexes quartiles. 
Waist circumference is a surrogate marker of abdominal 
fat mass. It correlates with subcutaneous and visceral 
fat mass and is related to increased cardiometabolic risk 
(25,26). 
In conclusion, the cut-off values identified in both 
models, HOMA1-IR and HOMA2-IR, for insulin re-
sistance and MS, have a clinical and epidemiological 
application for Westernized admixtured multi-ethnic 
populations. Given the association between insulin re-
sistance, obesity and classical components of MS in the 
total population and in apparently healthy individuals, 
the early detection of insulin resistance and MS using 
a simple tool like HOMA models is attractive. Effec-
tive interventions for improving insulin sensitivity and 
reducing abdominal obesity primarely by weight reduc-
tion and physical activity may help in preventing type 2 
diabetes and cardiovascular disease. 
Disclosure: No potential conflict of interest relevant to this article 
was reported.
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